Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis.
Level 5 - mechanism / opinion, no new human data
Preclinical bench and animal mechanistic research
PubMed 27892461 · doi:10.1038/ncomms13457
What was done
Method and design, investigated preclinical molecular mechanism of action, target activation requirements, and anti-atherosclerotic efficacy of bempedoic acid (ETC-1002). The authors tested whether ETC-1002 acts as a prodrug requiring activation by very long-chain acyl-CoA synthetase-1 (ACSVL1), examined the roles of ATP-citrate lyase (ACL) inhibition versus AMP-activated protein kinase (AMPK) activation in LDL receptor regulation and atherosclerosis attenuation, and evaluated ACSVL1 expression in skeletal muscle.
What was found
The abstract reports no numerical values or statistical metrics. Qualitatively, ETC-1002 was identified as a prodrug requiring ACSVL1 activation to modulate its targets. Inhibition of ACL led to upregulation of the LDL receptor, decreased LDL-C, and attenuated atherosclerosis independently of AMPK. ACSVL1 was shown to be absent in skeletal muscle.
Why it matters
This paper identifies the hepatic-specific activation pathway of bempedoic acid, providing a mechanistic explanation for how it reduces LDL-C while avoiding statin-associated muscle toxicity.
Limits
The study is entirely preclinical bench and animal research. The abstract reports no quantitative data, sample sizes, specific animal species, or human clinical outcome measurements.
Cited by
- supports Bempedoic acid is a prodrug that is inactive until metabolized by the liver, exerting its cholesterol synthesis inhibition exclusively within hepatocytes without affecting extrahepatic cells.